Stockscreener 앱 받기
52.55
0.07%
-0.085
전일 마감가:
$52.63
열려 있는:
$52.63
하루 거래량:
253.67K
Relative Volume:
0.08
시가총액:
$2.72B
수익:
$190.41M
순이익/손실:
$20.48M
주가수익비율:
235.84
EPS:
0.2228
순현금흐름:
$46.66M
1주 성능:
+0.66%
1개월 성능:
+55.81%
6개월 성능:
-18.17%
1년 성능:
-21.77%
1일 변동 폭
$52.53
$52.64
1주일 범위
$52.21
$52.69
52주 변동 폭
$29.43
$90.32
Soleno Therapeutics Inc Stock (SLNO) Company Profile
명칭
Soleno Therapeutics Inc
전화
650-213-8444
주소
100 MARINE PARKWAY, SUITE 400, REDWOOD CITY, CA
Compare SLNO vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SLNO
Soleno Therapeutics Inc
|
52.55 | 2.72B | 190.41M | 20.48M | 46.66M | 0.2228 |
VRTX
Vertex Pharmaceuticals Inc
|
436.05 | 110.97B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
750.33 | 79.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
800.13 | 49.73B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.19 | 42.98B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
310.52 | 34.37B | 5.36B | 287.73M | 924.18M | 2.5229 |
Soleno Therapeutics Inc Stock (SLNO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-18 | 개시 | Wolfe Research | Outperform |
| 2025-10-07 | 개시 | Goldman | Buy |
| 2025-08-20 | 개시 | Wells Fargo | Overweight |
| 2025-06-23 | 개시 | TD Cowen | Buy |
| 2025-03-05 | 재개 | Stifel | Buy |
| 2024-12-02 | 재확인 | Robert W. Baird | Outperform |
| 2024-12-02 | 재확인 | Stifel | Buy |
| 2024-09-03 | 개시 | H.C. Wainwright | Buy |
| 2024-05-10 | 개시 | Robert W. Baird | Outperform |
| 2024-02-05 | 개시 | Piper Sandler | Overweight |
| 2024-01-23 | 개시 | Stifel | Buy |
| 2023-11-21 | 재개 | Guggenheim | Buy |
| 2020-09-29 | 개시 | Guggenheim | Buy |
| 2020-01-10 | 개시 | Craig Hallum | Buy |
| 2019-12-23 | 개시 | Oppenheimer | Outperform |
| 2018-02-13 | 재확인 | Maxim Group | Buy |
모두보기
Soleno Therapeutics Inc 주식(SLNO)의 최신 뉴스
SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
SLNO SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors of Securities Class Action Deadline on May 5, 2026 - PR Newswire
Trading the Move, Not the Narrative: (SLNO) Edition - Stock Traders Daily
2026-04-12 | SLNO STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Soleno Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! | NDAQ:SLNO | Press Release - Stockhouse
NASDAQ: SLNO: Kessler Topaz Meltzer & Check, LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against Soleno Therapeutics, Inc. - The Globe and Mail
FinancialContentNASDAQ: SLNO: Kessler Topaz Meltzer & Check, LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against Soleno Therapeutics, Inc. - FinancialContent
SLNO INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors of Securities Class Action Deadline on May 5, 2026 - marketscreener.com
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionSLNO - ACCESS Newswire
Soleno Therapeutics, Inc. Notice of May 5, 2026 Application Deadline for Class Action LawsuitContact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline - PR Newswire
Neurocrine Biosciences, Inc. (NBIX) Soleno Therapeutics, Inc.M&A CallSlideshow (NASDAQ:NBIX) 2026-04-10 - Seeking Alpha
SLNO Shareholder Alert: Soleno Therapeutics, Inc. Securities Class Action Lawsuit Investors ... - Bluefield Daily Telegraph
SLNO Shareholder Alert: Soleno Therapeutics, Inc. - GlobeNewswire
INVESTOR NOTICE: Soleno Therapeutics (SLNO) Investors with Substantial Losses Have Opportunity to Lead Investor Class ActionHagens Berman - Sahm
TD Cowen Downgrades Soleno Therapeutics to 'Hold' - National Today
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Super Micro Computer, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
SLNO DEADLINE NOTICE: Soleno Therapeutics, Inc. Investors Encouraged to Contact Kirby McInerney LLP By May 5, 2026 - ACCESS Newswire
Rosen Law Firm Encourages Soleno Therapeutics Investors to Secure Counsel Before Deadline - National Today
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Soleno Therapeutics, Inc. Investors with ... - Caledonian Record
ROSEN, A LEADING LAW FIRM, Encourages Eos Energy Enterprises, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – EOSE - GlobeNewswire Inc.
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages - GlobeNewswire
SLNO Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors of Securities Class Action Deadline on May 5, 2026 - marketscreener.com
SOLENO LAWSUIT ALERT: Bragar Eagel & Squire, P.C. Announces - GlobeNewswire
Soleno Therapeutics Investors Seek Lead in Class Action Lawsuit - National Today
INVESTOR NOTICE: Soleno Therapeutics (SLNO) Investors with Subst - GuruFocus
Bronstein, Gewirtz & Grossman LLC Urges Soleno - GlobeNewswire
Soleno Therapeutics Shareholder Alert: ClaimsFiler Reminds - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Soleno Therapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesSLNO - PR Newswire
SOLENO THERAPEUTICS, INC. (SLNO) DEADLINE ALERT Bernstein - GlobeNewswire
Soleno Therapeutics (SLNO) still appears attractive despite slower US launch ramp projections - MSN
United StatesGoodwin Advises Centerview And Guggenheim On $2.9 Billion Sale Of Soleno Therapeutics To Neurocrine Biosciences - Mondaq
This Soleno Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Sahm
Soleno Therapeutics, Inc. INVESTIGATION: Kirby McInerney LLP Anno - The National Law Review
Soleno Therapeutics Inc. (SLNO) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit – RGRD Law - marketscreener.com
INVESTOR ALERT: Soleno Therapeutics Inc. (SLNO) Investors - GlobeNewswire
SLNO Stockholders Have Opportunity to Lead Soleno Therapeutics, I - The National Law Review
Soleno Therapeutics, Inc. (SLNO) Investors: May 5, 2026, Deadline in Securities Fraud Class Action Lawsuit - Morningstar
SLNO ALERT: Hagens Berman Alerts Soleno (SLNO) Investors to - GlobeNewswire
Soleno Therapeutics (NASDAQ:SLNO) Tracks Rating Downgrade Amid Nasdaq Index Activity - Kalkine Media
Soleno Therapeutics, Inc. (SLNO) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
Soleno Therapeutics Stock Rallies 56.4% in a Week: Here's Why - Yahoo Finance
SLNO Stockholders Have Opportunity to Lead Soleno Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
HC Wainwright & Co. downgrades Soleno Therapeutics (SLNO) - MSN
A Look At Soleno Therapeutics (SLNO) Valuation After Its Recent Share Price Surge - Sahm
Soleno Therapeutics, Inc. Notice of May 5, 2026 Application - GlobeNewswire
Gemini Space Station, Inc. Notice of May 18, 2026 Application Deadline for Class Action Lawsuit - GlobeNewswire Inc.
Enphase Energy, Inc. Notice of April 20, 2026 Application Deadline for Class Action Lawsuit - GlobeNewswire Inc.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Soleno Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – SLNO - ChartMill
Neurocrine Grows in Endocrinology, Rare Disease with $2.9B Soleno Buyout - Genetic Engineering and Biotechnology News
SLNO Investor Alert: Soleno Therapeutics, Inc. Securities Fraud LawsuitInvestors With Losses May Seek to Lead the Class Action After Company Allegedly Concealed Commercial Viability Risks: Levi & Korsinsky - Business Wire
Neurocrine’s $2.9B Soleno Buyout Brings What Could Become Its Next Blockbuster Drug - Dealbreaker
SLNO SHAREHOLDER UPDATE: Soleno (SLNO) Facing Securities Class Action After DCCR Launch Setback, Share Drop-- Hagens Berman - PR Newswire
Soleno Therapeutics Inc (SLNO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Soleno Therapeutics Inc 주식 (SLNO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Huang Michael F. | Sr. VP of Clinical Development |
Mar 27 '26 |
Sale |
30.44 |
6,582 |
200,365 |
39,823 |
0.62%
0.89%
자본화:
|
볼륨(24시간):